Further clinical validation studies are warranted in order to investigate if the methylation analyses of DOCK2, FBXO30, PFKP and/or cg12799885 may be used to improve PCa risk stratification at the time of diagnosis. This evidence concerns the gene FBXO30 and posterior cortical atrophy.